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Background
Retrovaccinology aims to employ neutralizing mono-
clonal antibodies isolated from natural infection to guide
design of immunogens that 're-elicit' similar neutralizing
specificities. With that aim, we are developing computa-
tional immunogen design methods that take as input a
crystal structure of an antibody-epitope complex and pro-
duce as output ''epitope-scaffold'' immunogens in which
the antibody-bound structure of the epitope is trans-
planted onto and stabilized by scaffold proteins. We
report our first results on scaffolding the V3 loop confor-
mation bound by mAb 447D.
Methods
Computational methods were developed within the
Rosetta modeling platform. Ten scaffolds were identified
by structural search of the Protein Data Bank and sub-
jected to backbone and sidechain grafting to transfer the
447D-bound epitope conformation.
Results
The three epitope-scaffolds with highest affinity for 447D
had dissociation constants from 2 to 15 nM as measured
by surface plasmon resonance. These three exhibited spe-
cificity for 447D in that they showed little or no binding
to 9 other anti-V3 monoclonals in Elisa. One epitope-scaf-
fold, from human Interleukin-4, was selected for immuni-
zation. Rabbits (N:3) were immunized with epitope-
scaffold DNA (0 and 4 weeks; 0.5 mg per animal per
immunization) and then with epitope-scaffold protein
(12, 19 and 25 weeks; 0.05 mg per animal per immuniza-
tion) mixed with Ribi. Antisera collected after the protein-
boost potently (IC50 > 250) neutralized HIV strains
exposing the consensus clade B V3 sequence, but did not
exhibit the full breadth of 447D itself.
Conclusion
The epitope-scaffold antisera represent the first potently
neutralizing response to a computationally designed HIV
antigen and demonstrate that computational design can
achieve desired immunological effects. Iterative methods
development with biophysical and immunological feed-
back promises to improve our ability to design immuno-
gens that elicit predictable neutralizing responses.
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